![](https://www.diabetesnews.com/wp-content/uploads/2014/07/diabetes-insulin-afrezza-150x150.jpg)
I have been using Afrezza, the new inhaled insulin developed by MannKind and marketed by Sanofi, for the last three and a half weeks. So far it’s… mysterious and exciting. Mysterious because the dosing seems ridiculously imprecise compared to the micro-unit counts I’m used to with an insulin pump.